A5032857366- Health Systems, Economic Evaluations, Quality of Life
- Urinary Bladder and Prostate Research
- Pelvic floor disorders treatments
- Cancer Genomics and Diagnostics
- Economic and Financial Impacts of Cancer
- Cardiovascular Syncope and Autonomic Disorders
- Hemophilia Treatment and Research
- Urinary Tract Infections Management
- BRCA gene mutations in cancer
- Bariatric Surgery and Outcomes
- Kidney Stones and Urolithiasis Treatments
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Race, History, and American Society
- Obesity and Health Practices
- Obesity, Physical Activity, Diet
- Uterine Myomas and Treatments
- Bladder and Urothelial Cancer Treatments
- Esophageal Cancer Research and Treatment
- Healthcare Systems and Practices
- Obstructive Sleep Apnea Research
- Diabetes Management and Research
- Clinical Laboratory Practices and Quality Control
- Frailty in Older Adults
- Health Promotion and Cardiovascular Prevention
- Diabetes Treatment and Management
Humana (United States)
2019-2022
University of Kentucky HealthCare
2019-2022
Cleveland Clinic
2021
Comprehensive Clinical Research
2017
Glaucoma is a progressive, irreversible disease that can lead to vision loss and lower quality of life if treatment not optimized. Effective glaucoma therapies are available intraocular pressure (IOP) minimize or delay progression. Nonetheless, adherence remains suboptimal for many patients.To identify potentially nonadherent patients evaluate the effect patient- physician-centric educational interventions on by using validated predictive model nonadherence medication.This prospective,...
The impact of formulary management strategies on utilization and expenditures in overactive bladder (OAB) treatment has not been extensively investigated. In 2013, step therapy (ST) policies for 2 branded OAB treatments, mirabegron fesoterodine, were removed from Humana Medicare Advantage Prescription Drug (MAPD) plans prescription drug (PDP), allowing an examination the effect ST medication use patterns costs.
Aim: Examine real-world characteristics, treatment patterns, and outcomes among treated persons with hemophilia A (PwHA) stratified by age. Patients & methods: This study utilized US claims data from 1 January 2007–31 July 2018 the Humana Research Database. Unadjusted comparisons were conducted across PwHA (<18, 18–55, 56–89 years) enrolled in commercial or Medicare Advantage Prescription Drug plans. Results: total of 294 identified; 21.1% experienced ≥1 bleeding event, 41.2 53.1% had...
Background: Patients with dementia commonly suffer from symptoms of overactive bladder (OAB); however, limited research exists on the clinical impact coexisting OAB among patients dementia. As such, objective this study was to examine outcomes, health-care resource use, and associated costs Methods: We conducted a retrospective cohort analysis using 3861 matched pairs without OAB. Analyses were based administrative claims data January 1, 2007, September 30, 2015, compared health services...
As continuous exposure to anticholinergics has been associated with adverse outcomes, accurately measuring is important. However, no gold standard measure available, and the performance of existing measures not compared. Our objective was compare properties Cumulative Anticholinergic Burden (CAB) against two anticholinergic assess their compatibility for use in observational studies based on claims data. The average daily dose, cumulative dose CAB were evaluated on: applicability burden...
PURPOSE To develop an approach to identify and evaluate recent use of multigene panel testing over time. METHODS We conducted a retrospective database analysis using medical pharmacy claims data. Medicare Advantage Prescription Drug Plan members diagnosed with select malignant solid tumors were identified. The pattern somatic genetic for each patient was evaluated from January 2016 through December 2018. Tests classified by the number genes tested in panel: < 50 (small or medium) ≥...
To evaluate the positive predictive value of claims-based V85 codes for identifying individuals with varying degrees BMI relative to their measured obtained from medical record abstraction.This was a retrospective validation study utilizing administrative claims and chart data 1 January 2009 31 August 2015. Randomly selected samples patients enrolled in Medicare Advantage Prescription Drug (MAPD) or commercial health plan claim were identified. The category (underweight, normal weight,...
BACKGROUND: Cardiovascular (CV) risk tools have been developed both nationally and internationally to identify patients at for developing CV disease or experiencing a event. However, these vary widely in the definitions of endpoints, time which endpoints are measured, patient populations, their validity. The primary limitation some most commonly utilized is lack specificity type 2 diabetes (T2D) population and/or among older patients. OBJECTIVE: To develop predictive model within an with T2D...
Journal Article FOREWORD FROM ONTARIO'S MINISTER OF HEALTH, CONFERENCE HOST Get access Elinor Caplan Ontario Minister of Health Search for other works by this author on: Oxford Academic PubMed Google Scholar International Quality in Care, Volume 2, Issue 1, March 1990, Pages 1–2, https://doi.org/10.1093/intqhc/2.1.1 Published: 01 1990
Background: Health-related quality of life (HRQoL) is an important patient-reported outcome to assess in patients with prostate cancer (PC). A variety general and disease-specific measures have been developed, but there a lack evidence on performance the Centers for Disease Control Prevention (CDC) Healthy Days (HDs) measure population metastatic disease relative other validated scales. Objective: To report understand HRQoL using HDs instrument PC taking novel oral therapies compare results...
Anticholinergic use is common in the elderly, and among patients with overactive bladder (OAB). We conducted a historical cohort study examining relationship between anticholinergic exposure intensity on risk of falls fractures based administrative claims data for Medicare Advantage members OAB. Patients newly diagnosed or treated OAB were identified followed until disenrollment end period. Primary outcome was combined endpoint consisting fractures. The Cognitive Burden (ACB) scale used to...
Current tools to identify patients at risk for cardiovascular (CV) disease or events are variable, limiting their utility and generalizability. The purpose of this study was develop a predictive model with type 2 diabetes (T2D) who ≥65 years age, enrolled in Medicare Advantage Prescription Drug (MAPD) plan future CV events. This retrospective cohort used administrative claims, laboratory enrollment data from 1/2011-12/2018. Patients T2D were identified 1/2012-12/2013 using diagnosis codes...
"CGE22-096: Trends in The Use of Comprehensive Genomic Profiling Among Older Patients With Advanced Cancer From 2018 to 2020 the United States: Findings SEQUENCE Study" published on 31 Mar 2022 by National Network.
9126 Background: As the number of approved molecularly-targeted therapies for treatment lung cancer increases, debate continues as to whether a clinical strategy leveraging next-generation sequencing (NGS) comprehensive genomic profiling (CGP) match patients targeted treatments is advantageous versus narrow/single-gene (N/S) panel testing. We examined and economic outcomes with advanced (aLC) in United States (US). Methods: In this retrospective study, newly diagnosed aLC aged 65-89 years...
Abstract Introduction/Purpose: Recent advances have led to approval of multiple new targeted drugs across a variety indications based on genomic markers. In part due the increasing number therapeutically actionable markers in many cancers, whether strategy upfront broad next-generation sequencing (NGS) could potentially improve selection patients for compared narrow/single gene panels remains uncertain. We examined recent trends proportions receiving sequencing-directed therapy following use...